SITC Annual Meeting 2024

Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. We are pleased to share our latest scientific and clinical research findings during SITC 2024.

Schedule a meeting with us

Tempus AI & Technology

Stop by our booth to discover how we are leveraging AI and technology to advance precision oncology

See the latest science and experience live demos around immune profile score (IPS).

Abstracts

Abstracts

November 7, 2024

Abstract #
149

First Authors
Abdul Rafeh Naqash, MD (Stephenson Cancer Center, University of Oklahoma Health Sciences Center), et al.

APSCR1::TFE3 Type 1 fusion isoform in alveolar soft part sarcoma (ASPS) displays an immunologically active tumor immune microenvironment (TIME) vs. type 2 fusion that could impact response to immune checkpoint inhibitors (ICIs)

November 8, 2024

Abstract #
149

First Authors
Abdul Rafeh Naqash, MD (Stephenson Cancer Center, University of Oklahoma Health Sciences Center), et al.

APSCR1::TFE3 Type 1 fusion isoform in alveolar soft part sarcoma (ASPS) displays an immunologically active tumor immune microenvironment (TIME) vs. type 2 fusion that could impact response to immune checkpoint inhibitors (ICIs)

Abstract #
1241

First Authors
Geoffrey Schau (Tempus AI, Inc.), et al.

Self-Supervised Representation Learning Enables Genomic Prediction at Single-Organoid Resolution

Abstract #
589

First Authors
Julian R. Molina, (Mayo Clinic), et al.

BASECAMP-1 is an efficient pre-screening study that identifies patients with HLA LOH and provides mutational, RNA-Seq, and microbiome data for precision logic-gated CAR T therapeutic trials

Abstract #
627

First Authors
Julian R. Molina (Mayo Clinic, Rochester), et al.

EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity

November 9, 2024

Abstract #
188

First Authors
Alia Zander, PhD (Tempus AI, Inc.), et al.

Clinical validation of a novel multi-omic algorithm for stratifying outcomes in a real-world cohort of metastatic solid cancer patients treated with immune checkpoint inhibitors

Abstract #
166

First Authors
Sebastià Franch-Expósito, PhD (Tempus AI, Inc.), et al.

POLE/POLD1 Mutations as Predictive Biomarkers for Immunotherapy Response: Insights from a Pan-cancer Real-World Dataset

Abstract #
884

First Authors
Mario G Rosasco, PhD (Tempus AI, Inc.), et al.

Variable associations between humoral immune features and immune checkpoint blockade-related outcomes across tissues in metastatic lung adenocarcinoma

Abstract #
588

First Authors
Patrick M. Grierson (Washington University), et al.

EVEREST-1: Initial safety data from a seamless phase 1/2 study of A2B530, a logic- gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH

Abstract #
1352

First Authors
Zach Rivers (Tempus AI, Inc.), et al.

Impact of timing of real-world CT imaging on cost-effectiveness of a molecular biomarker for treatment response monitoring of immunotherapy

Schedule a meeting with us

We'll be in touch shortly.